What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge - Yahoo Finance
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge Yahoo Finance
Eli Lilly Company News
Lilly buys non-opioid pain drugmaker 4E - BioPharma Dive
Lilly buys non-opioid pain drugmaker 4E BioPharma Dive
Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio - Insider Monkey
Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio Insider Monkey
Should You Buy Eli Lilly Stock Now or Wait for a Dip? - The Motley Fool
Should You Buy Eli Lilly Stock Now or Wait for a Dip? The Motley Fool
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished - Trefis
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished Trefis
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setup - ChartMill
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setup ChartMill
Eli Lilly (LLY) Stock After Huge GLP 1 Expectations And 7x Five Year Run - simplywall.st
Eli Lilly (LLY) Stock After Huge GLP 1 Expectations And 7x Five Year Run simplywall.st
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. - Barron's
Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Barron's
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why - MassLive
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why MassLive
Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company investor.lilly.com
Eli Lilly to buy three small vaccine developers - statnews.com
Eli Lilly to buy three small vaccine developers statnews.com
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data - Investing.com
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data Investing.com
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market? - Yahoo Finance
Can Retatrutide Extend Eli Lilly and Co (LLY)’s Lead in Weight Loss Market? Yahoo Finance
Eli Lilly issues data sharing ultimatum to 340B hospitals - Healthcare Dive
Eli Lilly issues data sharing ultimatum to 340B hospitals Healthcare Dive
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas - CNBC
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas CNBC
Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show - KFF Health News
Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show KFF Health News
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company - investor.lilly.com
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company investor.lilly.com
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors - Yahoo Finance
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors Yahoo Finance
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility - investor.lilly.com
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility investor.lilly.com
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis - Fox 59
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis Fox 59
Trump bought Lilly stock as his admin boosted its obesity drugs - USA Today
Trump bought Lilly stock as his admin boosted its obesity drugs USA Today
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes - investor.lilly.com
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes investor.lilly.com
Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper - Reuters
Lilly to halve planned €2.3 billion investment in Germany, CEO tells newspaper Reuters
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial - statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial statnews.com
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis - PR Newswire
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis PR Newswire
Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts - statnews.com
Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts statnews.com
Eli Lilly tops prominent rankings on pharma R&D performance - statnews.com
Eli Lilly tops prominent rankings on pharma R&D performance statnews.com
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - investor.lilly.com
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 investor.lilly.com
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance | Eli Lilly and Company - investor.lilly.com
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance | Eli Lilly and Company investor.lilly.com
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. - Yahoo Finance
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. Yahoo Finance
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company - investor.lilly.com
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies | Eli Lilly and Company investor.lilly.com
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. - The Motley Fool
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. The Motley Fool
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says - NBC News
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says NBC News
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company - investor.lilly.com
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | Eli Lilly and Company investor.lilly.com
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial - BioPharma Dive
Lilly’s triple-acting obesity drug hits goal in Phase 3 trial BioPharma Dive
Eli Lilly Just Announced Fantastic News for Shareholders - The Motley Fool
Eli Lilly Just Announced Fantastic News for Shareholders The Motley Fool
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines - investor.lilly.com
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines investor.lilly.com
Are analysts too quick to gloss over Lilly’s liver case? - statnews.com
Are analysts too quick to gloss over Lilly’s liver case? statnews.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Bloomberg.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act Bloomberg.com